Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
Canadian pancreatic cancer researchers, including a team at the Princess Margaret Cancer Centre, are joining forces under a Terry Fox Research Institute initiative bringing new hope for patients with this deadly disease.
"For many years it's been hopeless from a patient perspective, and we are hoping to help shift this," says Dr. Daniel Renouf of BC Cancer Agency and the University of British Columbia (UBC) who, along with Dr. David Schaeffer of the Vancouver General Hospital and UBC, is leading a $5-million pan-Canadian, precision medicine initiative.
In addition to Drs. Renouf and Schaeffer, other study Principal Investigators are: Drs. Jennifer Knox and Steven Gallinger of the Princess Margaret and Ontario Institute for Cancer Research (OICR), Dr. George Zogopoulos of the McGill University Health Centre and Dr. Oliver Bathe of the Tom Baker Cancer Centre and the University of Calgary.
A lack of early detection tests. Few known symptoms. Very limited treatment options. No known biomarkers that can be used to direct therapy. These are among the clinical challenges team EPPIC, short for Enhanced Pancreatic Cancer Profiling for Individualized Care, is tackling over the next five years to improve personalized treatments for patients with pancreatic ductal adenocarcinoma (PDAC), a disease with a five-year survival rate of just nine per cent.
"Our project focuses on metastatic cancer versus surgically resectable primary tumours, because this is the clinical problem we see most often," says Dr. Schaeffer, noting a priority is to discern if the metastatic and primary tumour differ in their genetic make-up.
Four out of five patients have metastatic cancer at the time of diagnosis and most will succumb within a year.
This project is currently under way in Toronto and Vancouver, and is expanding to include up to 400 eligible patients in Montreal, Kingston, Ottawa, Calgary, and Edmonton.
More than 100 patients from the McCain Centre for Pancreatic Cancer at the Princess Margaret have already participated in the COMPASS trial, initially funded by OICR, Pancreatic Cancer Canada (PCC) and The Princess Margaret Cancer Foundation. Early results were published in late 2017 in Clinical Cancer Research.
"Only with national collaboration can we move forward at pace with global understanding of this disease and make a significant contribution," says Dr. Knox, Principal Investigator of COMPASS and co-Director of the McCain Centre.
"We love the idea that more Canadians will have the opportunity to potentially impact their care while contributing to scientific advancement."
Genomic sequencing and bioinformatics analyses of patient tumours will be conducted at the OICR and the BC Cancer Genome Sciences Centre.
Many of the EPPIC team's investigators are members of PancOne, an initiative of PCC bringing together pancreas researchers from across the country. The foundational funding from PCC has also been integral in establishing a strong framework from which to build pan-Canadian collaboration.